JO
SKYE icon

John Overdeck’s Skye Bioscience SKYE Stock Holding History

John Overdeck’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-25,684
Closed -$15.8K – 5507
2026
Q1 		$15.8K Sell
25,684
-26,022
-50% -$21.2K ﹤0.01% 4517
2025
Q4 		$38.8K Sell
51,706
-40,612
-44% -$59.3K ﹤0.01% 3961
2025
Q3 		$363K Buy
92,318
+29,163
+46% +$110K ﹤0.01% 3131
2025
Q2 		$264K Buy
63,155
+46,548
+280% +$96.3K ﹤0.01% 2835
2025
Q1 		$26.4K Buy
+16,607
New +$45.3K ﹤0.01% 3087

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

John Overdeck's SKYE Position: Q2 2026 in Review

John Overdeck sold out of Skye Bioscience (SKYE) in Q2 2026, closing a stake of 25,684 shares — an estimated $15.8K sold.

John Overdeck first reported a position in SKYE in Q1 2025 and held it in 5 quarters. The position peaked at $363K in Q3 2025. 43 funds tracked by Wall St. Rank hold SKYE as of Q2 2026.

  • John Overdeck reported no remaining Skye Bioscience position as of Q2 2026 after selling out during the quarter.
  • John Overdeck sold 25,684 Skye Bioscience shares in Q2 2026, an estimated $15.8K.
  • John Overdeck first reported a position in Skye Bioscience in Q1 2025 and held it in 5 quarters.
  • John Overdeck's Skye Bioscience position peaked at $363K in Q3 2025.
  • 43 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.